1. Home
  2. ALTS vs NKTX Comparison

ALTS vs NKTX Comparison

Compare ALTS & NKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALTS
  • NKTX
  • Stock Information
  • Founded
  • ALTS 1976
  • NKTX 2015
  • Country
  • ALTS United States
  • NKTX United States
  • Employees
  • ALTS N/A
  • NKTX N/A
  • Industry
  • ALTS
  • NKTX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALTS
  • NKTX Health Care
  • Exchange
  • ALTS NYSE
  • NKTX Nasdaq
  • Market Cap
  • ALTS 109.1M
  • NKTX 123.5M
  • IPO Year
  • ALTS N/A
  • NKTX 2020
  • Fundamental
  • Price
  • ALTS $9.47
  • NKTX $1.77
  • Analyst Decision
  • ALTS
  • NKTX Strong Buy
  • Analyst Count
  • ALTS 0
  • NKTX 6
  • Target Price
  • ALTS N/A
  • NKTX $14.40
  • AVG Volume (30 Days)
  • ALTS 321.4K
  • NKTX 422.2K
  • Earning Date
  • ALTS 08-18-2025
  • NKTX 08-12-2025
  • Dividend Yield
  • ALTS N/A
  • NKTX N/A
  • EPS Growth
  • ALTS N/A
  • NKTX N/A
  • EPS
  • ALTS N/A
  • NKTX N/A
  • Revenue
  • ALTS $18,046,000.00
  • NKTX N/A
  • Revenue This Year
  • ALTS $185.91
  • NKTX N/A
  • Revenue Next Year
  • ALTS $64.93
  • NKTX N/A
  • P/E Ratio
  • ALTS N/A
  • NKTX N/A
  • Revenue Growth
  • ALTS N/A
  • NKTX N/A
  • 52 Week Low
  • ALTS $1.29
  • NKTX $1.31
  • 52 Week High
  • ALTS $10.95
  • NKTX $8.23
  • Technical
  • Relative Strength Index (RSI)
  • ALTS 56.66
  • NKTX 46.34
  • Support Level
  • ALTS $8.16
  • NKTX $1.76
  • Resistance Level
  • ALTS $10.80
  • NKTX $2.08
  • Average True Range (ATR)
  • ALTS 1.06
  • NKTX 0.11
  • MACD
  • ALTS -0.20
  • NKTX -0.00
  • Stochastic Oscillator
  • ALTS 46.77
  • NKTX 25.00

About ALTS ALT5 SIGMA CORPORATION

ALT5 Sigma Corp is a fintech company. The company operates in three operating segments: Fintech: provides next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, Biotechnology: Biotechnology segment is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties; Corporate and Others: Corporate and Other segment consists of certain corporate general and administrative costs. Company has revenue from Fintech Segment.

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Share on Social Networks: